GEN Exclusives

More »

GEN News Highlights

More »
Mar 22, 2007

Vion Extends Manufacturing Agreement with SAFC

  • Vion Pharmaceuticals extended its manufacturing agreement with SAFC for its lead anticancer agent, Cloretazine®, to September 2009. SAFC will continue to manufacture Cloretazine active pharmaceutical ingredient (API).

    In December 2006, Vion entered into a manufacturing agreement for Cloretazine finished drug product with Ben Venue Laboratories. Ben Venue will manufacture Cloretazine finished drug product using API manufactured by SAFC.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Value-Pricing Cancer Drugs

Do you think all new cancer drugs awaiting approval should undergo value-pricing?

More »